Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.70 Bil Enterprise Value: 10.12 Bil PE Ratio: 113.19 PB Ratio: 2.90 GF Score: 82/100

Qiagen NV at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 12:00PM GMT
Release Date Price: €39.76 (+0.05%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

Hi. Good morning, everyone. My name is Matt Sykes with Goldman Sachs. I'm the senior research analyst for the life sciences tools and diagnostics sector. And this morning, we're happy to kick off the 42nd Annual Goldman Sachs Global Healthcare Conference with QIAGEN.

With me, I have Roland Sackers, the Chief Financial Officer; John Gilardi, the Vice President, Head of Corporate Communications, Investor Relations; and Phoebe Loh, the Senior Director of Investor Relations.

Thank you, everyone, for joining us.

I thought maybe what we start out is I kind of turn it over to you, Roland, to set the stage for us to talk about perhaps the most recent quarter, expectations for the year, and just kind of set us up with how you're thinking about things these days.

Roland Sackers
QIAGEN N.V. - CFO, MD & Member of Management Board

Yes. Thanks, Matt. And again, thanks for having us. And as I said before, I'm very much looking forward to a real-life

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot